Modifications of residual viraemia in human immunodeficiency virus-1-infected subjects undergoing repeated highly active antiretroviral therapy interruptions
Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanità, Rome, Italy Correspondence Lucia Palmisano lucia.palmisano{at}iss.it Received July 2, 2008 Accepted September 30, 2008 Residual viraemia is detectable in the majority of human immunodeficiency virus (HIV)-infe...
Gespeichert in:
| Veröffentlicht in: | Journal of medical microbiology 2009-01, Vol.58 (1), p.121-124 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 124 |
|---|---|
| container_issue | 1 |
| container_start_page | 121 |
| container_title | Journal of medical microbiology |
| container_volume | 58 |
| creator | Palmisano, Lucia Giuliano, Marina Bucciardini, Raffaella Andreotti, Mauro Fragola, Vincenzo Pirillo, Maria F Weimer, Liliana E Mancini, Maria G Vella, Stefano |
| description | Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanità, Rome, Italy
Correspondence Lucia Palmisano lucia.palmisano{at}iss.it
Received July 2, 2008
Accepted September 30, 2008
Residual viraemia is detectable in the majority of human immunodeficiency virus (HIV)-infected subjects with plasma HIV-1 RNA |
| doi_str_mv | 10.1099/jmm.0.004630-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66736881</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20343317</sourcerecordid><originalsourceid>FETCH-LOGICAL-c426t-6a9b163b853dc7d037acc85a62484987c1cc8dae6e6549beb902cbfe9c5288093</originalsourceid><addsrcrecordid>eNqFkU2v1CAYhYnReMfRrUvDRl115Ku0LM2NX8k1bnRNKH07w6TACOXezI_xv0qdiS4NCyA8nPPmHIReUrKjRKl3R-93ZEeIkJw05BHaUNHxppVCPEYbQhhrmKTtDXqW85EQ2nGunqIbqkgnpOQb9OtrHN3krFlcDBnHCSfIbixmxvcuGfDOYBfwoXgTsPO-hDhC5R0Ee16RkhvauDCBXWDEuQzHesq4hBHSPrqwr4InMOvjwe0P8xkbu7h7wCYsLsGS4uoz4-UAyZzO1WyBlMrpzzzP0ZPJzBleXPct-vHxw_fbz83dt09fbt_fNVYwuTTSqIFKPvQtH203Et4Za_vWSCZ6ofrO0nodDUiQrVADDIowO0ygbMv6nii-RW8uuqcUfxbIi_YuW5hnEyCWrKXsuOx7-l-QES44rzFv0e4C2hRzTjDpU3LepLOmRK_N6dqcJvrSnCb1w6urchk8jP_wa1UVeH0FTLZmnpIJ1uW_HKNkXaJyby_cGvdDjVjvIXhX5xhcXF3bXlNNGeW_ARDctHc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20343317</pqid></control><display><type>article</type><title>Modifications of residual viraemia in human immunodeficiency virus-1-infected subjects undergoing repeated highly active antiretroviral therapy interruptions</title><source>MEDLINE</source><source>Microbiology Society</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Palmisano, Lucia ; Giuliano, Marina ; Bucciardini, Raffaella ; Andreotti, Mauro ; Fragola, Vincenzo ; Pirillo, Maria F ; Weimer, Liliana E ; Mancini, Maria G ; Vella, Stefano</creator><creatorcontrib>Palmisano, Lucia ; Giuliano, Marina ; Bucciardini, Raffaella ; Andreotti, Mauro ; Fragola, Vincenzo ; Pirillo, Maria F ; Weimer, Liliana E ; Mancini, Maria G ; Vella, Stefano</creatorcontrib><description>Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanità, Rome, Italy
Correspondence Lucia Palmisano lucia.palmisano{at}iss.it
Received July 2, 2008
Accepted September 30, 2008
Residual viraemia is detectable in the majority of human immunodeficiency virus (HIV)-infected subjects with plasma HIV-1 RNA <50 copies ml –1 . In the present study, the impact of repeated treatment interruptions on residual HIV-1 viraemia was investigated in 58 subjects enrolled in the ISS-PART, a multicentre, randomized clinical trial comparing 24 months of continuous (arm A) and intermittent (arm B) highly active antiretroviral therapy (HAART). Residual viraemia was measured by a modified Roche Amplicor HIV-1 RNA assay (limit of detection 2.5 copies ml –1 ). At baseline, the median value of residual viraemia was 2.5 copies ml –1 in both arms; after 24 months, the median value was 2.5 in arm A and 8.3 in arm B. The median change from baseline to month 24 was significantly different between patients under continuous or intermittent HAART: 0 copies ml –1 (range –125.2 to +82.7) of HIV-1 RNA in arm A versus 2.1 copies ml –1 (range –80 to +46.8) in arm B ( P =0.024). These results suggest that intermittent HAART tends to modify HIV-1 viraemia set point even if a virological response is achieved after HAART reinstitution.
Abbreviations: HAART, highly active antiretroviral therapy; STIs, Structured Treatment Interruptions.</description><identifier>ISSN: 0022-2615</identifier><identifier>EISSN: 1473-5644</identifier><identifier>DOI: 10.1099/jmm.0.004630-0</identifier><identifier>PMID: 19074663</identifier><identifier>CODEN: JMMIAV</identifier><language>eng</language><publisher>Reading: Soc General Microbiol</publisher><subject>Adult ; Anti-HIV Agents - administration & dosage ; Anti-HIV Agents - therapeutic use ; Antiretroviral Therapy, Highly Active ; Biological and medical sciences ; Female ; Fundamental and applied biological sciences. Psychology ; HIV Infections - drug therapy ; HIV Infections - virology ; HIV-1 ; Human immunodeficiency virus 1 ; Human viral diseases ; Humans ; Infectious diseases ; Male ; Medical sciences ; Microbiology ; Middle Aged ; RNA, Viral - blood ; Viral diseases ; Viral diseases of the lymphoid tissue and the blood. Aids ; Viremia</subject><ispartof>Journal of medical microbiology, 2009-01, Vol.58 (1), p.121-124</ispartof><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c426t-6a9b163b853dc7d037acc85a62484987c1cc8dae6e6549beb902cbfe9c5288093</citedby><cites>FETCH-LOGICAL-c426t-6a9b163b853dc7d037acc85a62484987c1cc8dae6e6549beb902cbfe9c5288093</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,3746,3747,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21010104$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19074663$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Palmisano, Lucia</creatorcontrib><creatorcontrib>Giuliano, Marina</creatorcontrib><creatorcontrib>Bucciardini, Raffaella</creatorcontrib><creatorcontrib>Andreotti, Mauro</creatorcontrib><creatorcontrib>Fragola, Vincenzo</creatorcontrib><creatorcontrib>Pirillo, Maria F</creatorcontrib><creatorcontrib>Weimer, Liliana E</creatorcontrib><creatorcontrib>Mancini, Maria G</creatorcontrib><creatorcontrib>Vella, Stefano</creatorcontrib><title>Modifications of residual viraemia in human immunodeficiency virus-1-infected subjects undergoing repeated highly active antiretroviral therapy interruptions</title><title>Journal of medical microbiology</title><addtitle>J Med Microbiol</addtitle><description>Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanità, Rome, Italy
Correspondence Lucia Palmisano lucia.palmisano{at}iss.it
Received July 2, 2008
Accepted September 30, 2008
Residual viraemia is detectable in the majority of human immunodeficiency virus (HIV)-infected subjects with plasma HIV-1 RNA <50 copies ml –1 . In the present study, the impact of repeated treatment interruptions on residual HIV-1 viraemia was investigated in 58 subjects enrolled in the ISS-PART, a multicentre, randomized clinical trial comparing 24 months of continuous (arm A) and intermittent (arm B) highly active antiretroviral therapy (HAART). Residual viraemia was measured by a modified Roche Amplicor HIV-1 RNA assay (limit of detection 2.5 copies ml –1 ). At baseline, the median value of residual viraemia was 2.5 copies ml –1 in both arms; after 24 months, the median value was 2.5 in arm A and 8.3 in arm B. The median change from baseline to month 24 was significantly different between patients under continuous or intermittent HAART: 0 copies ml –1 (range –125.2 to +82.7) of HIV-1 RNA in arm A versus 2.1 copies ml –1 (range –80 to +46.8) in arm B ( P =0.024). These results suggest that intermittent HAART tends to modify HIV-1 viraemia set point even if a virological response is achieved after HAART reinstitution.
Abbreviations: HAART, highly active antiretroviral therapy; STIs, Structured Treatment Interruptions.</description><subject>Adult</subject><subject>Anti-HIV Agents - administration & dosage</subject><subject>Anti-HIV Agents - therapeutic use</subject><subject>Antiretroviral Therapy, Highly Active</subject><subject>Biological and medical sciences</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - virology</subject><subject>HIV-1</subject><subject>Human immunodeficiency virus 1</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Microbiology</subject><subject>Middle Aged</subject><subject>RNA, Viral - blood</subject><subject>Viral diseases</subject><subject>Viral diseases of the lymphoid tissue and the blood. Aids</subject><subject>Viremia</subject><issn>0022-2615</issn><issn>1473-5644</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU2v1CAYhYnReMfRrUvDRl115Ku0LM2NX8k1bnRNKH07w6TACOXezI_xv0qdiS4NCyA8nPPmHIReUrKjRKl3R-93ZEeIkJw05BHaUNHxppVCPEYbQhhrmKTtDXqW85EQ2nGunqIbqkgnpOQb9OtrHN3krFlcDBnHCSfIbixmxvcuGfDOYBfwoXgTsPO-hDhC5R0Ee16RkhvauDCBXWDEuQzHesq4hBHSPrqwr4InMOvjwe0P8xkbu7h7wCYsLsGS4uoz4-UAyZzO1WyBlMrpzzzP0ZPJzBleXPct-vHxw_fbz83dt09fbt_fNVYwuTTSqIFKPvQtH203Et4Za_vWSCZ6ofrO0nodDUiQrVADDIowO0ygbMv6nii-RW8uuqcUfxbIi_YuW5hnEyCWrKXsuOx7-l-QES44rzFv0e4C2hRzTjDpU3LepLOmRK_N6dqcJvrSnCb1w6urchk8jP_wa1UVeH0FTLZmnpIJ1uW_HKNkXaJyby_cGvdDjVjvIXhX5xhcXF3bXlNNGeW_ARDctHc</recordid><startdate>20090101</startdate><enddate>20090101</enddate><creator>Palmisano, Lucia</creator><creator>Giuliano, Marina</creator><creator>Bucciardini, Raffaella</creator><creator>Andreotti, Mauro</creator><creator>Fragola, Vincenzo</creator><creator>Pirillo, Maria F</creator><creator>Weimer, Liliana E</creator><creator>Mancini, Maria G</creator><creator>Vella, Stefano</creator><general>Soc General Microbiol</general><general>Society for General Microbiology</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20090101</creationdate><title>Modifications of residual viraemia in human immunodeficiency virus-1-infected subjects undergoing repeated highly active antiretroviral therapy interruptions</title><author>Palmisano, Lucia ; Giuliano, Marina ; Bucciardini, Raffaella ; Andreotti, Mauro ; Fragola, Vincenzo ; Pirillo, Maria F ; Weimer, Liliana E ; Mancini, Maria G ; Vella, Stefano</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c426t-6a9b163b853dc7d037acc85a62484987c1cc8dae6e6549beb902cbfe9c5288093</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adult</topic><topic>Anti-HIV Agents - administration & dosage</topic><topic>Anti-HIV Agents - therapeutic use</topic><topic>Antiretroviral Therapy, Highly Active</topic><topic>Biological and medical sciences</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - virology</topic><topic>HIV-1</topic><topic>Human immunodeficiency virus 1</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Microbiology</topic><topic>Middle Aged</topic><topic>RNA, Viral - blood</topic><topic>Viral diseases</topic><topic>Viral diseases of the lymphoid tissue and the blood. Aids</topic><topic>Viremia</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Palmisano, Lucia</creatorcontrib><creatorcontrib>Giuliano, Marina</creatorcontrib><creatorcontrib>Bucciardini, Raffaella</creatorcontrib><creatorcontrib>Andreotti, Mauro</creatorcontrib><creatorcontrib>Fragola, Vincenzo</creatorcontrib><creatorcontrib>Pirillo, Maria F</creatorcontrib><creatorcontrib>Weimer, Liliana E</creatorcontrib><creatorcontrib>Mancini, Maria G</creatorcontrib><creatorcontrib>Vella, Stefano</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of medical microbiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Palmisano, Lucia</au><au>Giuliano, Marina</au><au>Bucciardini, Raffaella</au><au>Andreotti, Mauro</au><au>Fragola, Vincenzo</au><au>Pirillo, Maria F</au><au>Weimer, Liliana E</au><au>Mancini, Maria G</au><au>Vella, Stefano</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Modifications of residual viraemia in human immunodeficiency virus-1-infected subjects undergoing repeated highly active antiretroviral therapy interruptions</atitle><jtitle>Journal of medical microbiology</jtitle><addtitle>J Med Microbiol</addtitle><date>2009-01-01</date><risdate>2009</risdate><volume>58</volume><issue>1</issue><spage>121</spage><epage>124</epage><pages>121-124</pages><issn>0022-2615</issn><eissn>1473-5644</eissn><coden>JMMIAV</coden><abstract>Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanità, Rome, Italy
Correspondence Lucia Palmisano lucia.palmisano{at}iss.it
Received July 2, 2008
Accepted September 30, 2008
Residual viraemia is detectable in the majority of human immunodeficiency virus (HIV)-infected subjects with plasma HIV-1 RNA <50 copies ml –1 . In the present study, the impact of repeated treatment interruptions on residual HIV-1 viraemia was investigated in 58 subjects enrolled in the ISS-PART, a multicentre, randomized clinical trial comparing 24 months of continuous (arm A) and intermittent (arm B) highly active antiretroviral therapy (HAART). Residual viraemia was measured by a modified Roche Amplicor HIV-1 RNA assay (limit of detection 2.5 copies ml –1 ). At baseline, the median value of residual viraemia was 2.5 copies ml –1 in both arms; after 24 months, the median value was 2.5 in arm A and 8.3 in arm B. The median change from baseline to month 24 was significantly different between patients under continuous or intermittent HAART: 0 copies ml –1 (range –125.2 to +82.7) of HIV-1 RNA in arm A versus 2.1 copies ml –1 (range –80 to +46.8) in arm B ( P =0.024). These results suggest that intermittent HAART tends to modify HIV-1 viraemia set point even if a virological response is achieved after HAART reinstitution.
Abbreviations: HAART, highly active antiretroviral therapy; STIs, Structured Treatment Interruptions.</abstract><cop>Reading</cop><pub>Soc General Microbiol</pub><pmid>19074663</pmid><doi>10.1099/jmm.0.004630-0</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-2615 |
| ispartof | Journal of medical microbiology, 2009-01, Vol.58 (1), p.121-124 |
| issn | 0022-2615 1473-5644 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_66736881 |
| source | MEDLINE; Microbiology Society; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Adult Anti-HIV Agents - administration & dosage Anti-HIV Agents - therapeutic use Antiretroviral Therapy, Highly Active Biological and medical sciences Female Fundamental and applied biological sciences. Psychology HIV Infections - drug therapy HIV Infections - virology HIV-1 Human immunodeficiency virus 1 Human viral diseases Humans Infectious diseases Male Medical sciences Microbiology Middle Aged RNA, Viral - blood Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids Viremia |
| title | Modifications of residual viraemia in human immunodeficiency virus-1-infected subjects undergoing repeated highly active antiretroviral therapy interruptions |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T19%3A29%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Modifications%20of%20residual%20viraemia%20in%20human%20immunodeficiency%20virus-1-infected%20subjects%20undergoing%20repeated%20highly%20active%20antiretroviral%20therapy%20interruptions&rft.jtitle=Journal%20of%20medical%20microbiology&rft.au=Palmisano,%20Lucia&rft.date=2009-01-01&rft.volume=58&rft.issue=1&rft.spage=121&rft.epage=124&rft.pages=121-124&rft.issn=0022-2615&rft.eissn=1473-5644&rft.coden=JMMIAV&rft_id=info:doi/10.1099/jmm.0.004630-0&rft_dat=%3Cproquest_cross%3E20343317%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20343317&rft_id=info:pmid/19074663&rfr_iscdi=true |